Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. - Wikidata - wikimedia - TriplyDB

Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.

Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.

http://www.wikidata.org/entity/Q33401023

about

The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer Epigenetics Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?Immunotoxin - a new treatment option in patients with relapsed and refractory Hodgkin lymphoma Customized targeted therapy in Hodgkin lymphoma: hype or hope?New and emerging HDAC inhibitors for cancer treatment Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy Exploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation Assays Pediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine.Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients.Panobinostat in lymphoid and myeloid malignancies.A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma.Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma.Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies Genetic methylation and lymphoid malignancies: biomarkers of tumor progression and targeted therapy.The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells Ritonavir acts synergistically with panobinostat to enhance histone acetylation and inhibit renal cancer growth.Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management.The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines.Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells.A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma.Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors.Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update.Challenges and perspective of drug repurposing strategies in early phase clinical trials.Role of hematopoietic stem cell transplantation in relapsed/refractory hodgkin lymphoma Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer management.Marine-derived angiogenesis inhibitors for cancer therapy.Relapsed Hodgkin lymphoma: management strategies Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.

P2860

Q26745842-B5B34113-628B-43B5-9F49-CBD4B415A734 Q26749421-AD8C64BF-459D-4F80-9BF0-8061021E328C Q26770716-DBD7411E-5B15-4952-9507-FEF4826605BC Q26771601-588EEF39-812E-40C7-80CB-EF0C32CF099B Q26772848-E01A5581-01AC-4CF7-8B06-46F702B7DF69 Q27002554-9DCFAA02-7EDA-47D5-ADCD-5BD9F0EA061B Q27022413-52ACA17B-EDF5-4937-83A0-5802BAF3F002 Q27022992-FDFC5A9E-C721-4FF8-8F5A-5F96ECCF5284 Q28082536-3E5594FA-F28E-4705-BC45-67483D97908D Q28550025-320770F5-6B40-44EF-A5D2-1D0D44688C67 Q30248284-6172ABCE-B895-484F-9BFA-C9A4F7757B70 Q33405714-CC1A8818-4570-4B47-B558-D9A27E27CD13 Q33405891-4A62A7A3-EF22-4B0C-B088-EF2593246B9A Q33408889-0A21C23E-F988-497B-A917-F4741C27FDB0 Q33409579-987C337B-894D-4C52-BCB1-9A9967E6BFEE Q33410761-ED8A40A1-D13E-4C0F-B218-F0208A041B22 Q33411127-6ABACF17-5D53-45AC-B358-8F3A54760B14 Q33420273-0F3DEF78-DE9F-4F79-B3BC-E8CAE55FBDE5 Q33432027-FD6C2953-C480-4659-9FFB-E958B7233045 Q33432714-A5BA4DB4-1D0B-4EE8-959E-332369F44C19 Q33442755-8C414C61-ED99-4869-92CE-950C1FC541A1 Q33704061-D887F0CC-D84D-4BA2-B2BD-B9E1FF4E6C16 Q33886267-EE4EF1A8-D24B-4373-A689-CBE1251F115B Q33913937-15F4E10C-D579-4F3E-8769-A895DE2C1581 Q33928765-5547E3D5-0E4A-4ABF-BB72-B0B48BD8AE98 Q34265747-11704878-3605-4F96-B4F8-63198F34B9FF Q34662648-42E59952-F36E-4C85-9D0F-3025A6098570 Q35053177-2D1CECF2-7077-42D1-BEA3-C461C898E3BC Q35214924-EF1D095B-AC80-45C1-AE8D-975A00320519 Q35273390-92D4FC33-BF9B-42B7-8C70-FFB5C6592B06 Q35561607-C99383E5-96A4-49EE-A19A-CD8F88999982 Q35603293-4E3F3F39-5DE2-4386-83E5-AC6AEAC26B5F Q35726371-4BCAE0A8-6AA5-494D-99FB-2FDDD82F1149 Q35863063-81BEF80A-713F-4009-B282-82AA09940CFB Q36404763-78B0C7A0-81FF-456D-9CA6-C6C2E8343237 Q36738463-B07E0582-B4C0-493F-97BC-E611C2CF6B27 Q36994177-4674C536-D349-4C40-800C-5C55882F2FD5 Q37008427-E12E7A05-81E6-4B53-9539-CB5766C74EF0 Q37060652-C8E068C1-3CF1-4EAB-B0E4-9AE0804682C3 Q37150016-98D88AB0-B3C9-43E3-8B5C-4697FD26B0D4

P2860

Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.

http://www.wikidata.org/entity/Q33401023

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Panobinostat in patients with ...... : results of a phase II study.

@ast

Panobinostat in patients with ...... : results of a phase II study.

@en

type

label

Panobinostat in patients with ...... : results of a phase II study.

@ast

Panobinostat in patients with ...... : results of a phase II study.

@en

prefLabel

Panobinostat in patients with ...... : results of a phase II study.

@ast

Panobinostat in patients with ...... : results of a phase II study.

@en

P1433

Q33401023-9B0C7915-DE3C-4506-94AA-846F7B7CB116

P1476

Q33401023-E00413F2-E013-4013-A7A0-90741A6CD2B1

P2093

Q33401023-1C6D834D-7855-4077-ABBE-F3FD6A20550A

Q33401023-530FA4D5-6399-43BD-810E-41BFFB0C0784

Q33401023-5660B5A8-EFCD-4B21-8CBE-E0198E32CE18

Q33401023-72198FE0-FD77-4CE4-9DE3-C45ACA2EF87D

Q33401023-9F0EF226-3E0B-4182-A708-EB0E9C11A808

Q33401023-A86D6552-CFC9-4653-91C4-81A1FECB8EFF

Q33401023-AEB1CEA2-D25B-41DF-A03D-A7E8F8112BB6

Q33401023-BCFBE343-997C-403E-87B8-BD3165C0386D

Q33401023-C3F19833-D2E4-405F-8418-E9B8EA54E9FA

Q33401023-DC041EF5-8978-4941-918B-F9A970A70E95

P304

Q33401023-9808A62D-3288-44FF-B858-3DB685A00020

P31

Q33401023-46521A07-CDCA-42AA-B1FF-4A69101DAC1C

P356

Q33401023-94CB92CB-8BEA-49A5-A886-91BFF58C06AE

P407

Q33401023-34CB5772-D576-4914-83E7-7A63B336FED3

P433

Q33401023-C137E1FE-CBB7-4481-A376-EB6CC13727D2

P478

Q33401023-0EDF69E3-AD59-4B6C-B3D1-15DAD7A4FF2A

P50

Q33401023-09DF6E4F-BD54-4CAB-B5CA-F2D999C99AE8

Q33401023-EC5B6F55-ED68-4300-B8D0-A1A2ACBEA15C

P577

Q33401023-EF4F6E4A-916D-4F59-8A72-366788C32BA6

P5875

Q33401023-59952820-0FB9-41B3-8889-B9D7C45C895F

P698

Q33401023-FC261378-EE64-4A91-9FFE-209D48C45AC3

P356

JCO.2011.38.1350

P1433

Journal of Clinical Oncology

P1476

Panobinostat in patients with ...... : results of a phase II study.

@en

P2093

Anas Younes

http://www.w3.org/2001/XMLSchema#string

Andreas Engert

http://www.w3.org/2001/XMLSchema#string

Angela Shen

http://www.w3.org/2001/XMLSchema#string

Anna Sureda

http://www.w3.org/2001/XMLSchema#string

Christophe Le Corre

http://www.w3.org/2001/XMLSchema#string

Dina Ben-Yehuda

http://www.w3.org/2001/XMLSchema#string

H Miles Prince

http://www.w3.org/2001/XMLSchema#string

Jennifer Gallagher

http://www.w3.org/2001/XMLSchema#string

Mark Kirschbaum

http://www.w3.org/2001/XMLSchema#string

Patrick Johnston

http://www.w3.org/2001/XMLSchema#string

P304

2197-2203

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2011.38.1350

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Pier Luigi Zinzani

P577

2012-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224871205

http://www.w3.org/2001/XMLSchema#string

P698

22547596

http://www.w3.org/2001/XMLSchema#string